Related Experiment Video
Updated: May 9, 2026
06:17
A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis
Published on: May 22, 2018
Hydroxysafflor yellow A ameliorates homocysteine-induced Alzheimer-like pathologic dysfunction and memory/synaptic
Ya-Qin Lu1, Yu Luo, Zhong-Fang He
11 Department of Neurology, First Hospital of Lanzhou University , Lanzhou, China .
Rejuvenation Research
|July 11, 2013
Summary
Hydroxysafflor yellow A (HSYA) shows protective effects against homocysteine (Hcy)-induced Alzheimer-like symptoms in rats. HSYA treatment attenuated amyloid-beta accumulation and improved cognitive function, suggesting its therapeutic potential for Alzheimer disease.
Area of Science:
- Neuroscience
- Pharmacology
- Biochemistry
Background:
- Homocysteine (Hcy) is implicated in Alzheimer disease (AD) pathogenesis, contributing to amyloid-beta (Aβ) accumulation, synaptic dysfunction, and memory impairment.
- Alzheimer disease is a prevalent neurodegenerative disorder affecting millions worldwide.
Purpose of the Study:
- To investigate the protective effects of hydroxysafflor yellow A (HSYA) against Hcy-induced pathological and behavioral deficits relevant to AD.
- To evaluate HSYA's impact on Aβ accumulation, synaptic function, and cognitive performance in a rat model.
Main Methods:
- Rats were administered homocysteine (Hcy) to induce AD-like pathology.
- Experimental groups received either Hcy alone, Hcy plus hydroxysafflor yellow A (HSYA), or HSYA alone.
- Control groups received normal saline.
- Measurements included Aβ accumulation, synaptic function assessment, and learning/memory tests.
Main Results:
- HSYA administration significantly attenuated Hcy-induced Aβ accumulation.
- HSYA treatment improved synaptic function in rats exposed to Hcy.
- HSYA reversed Hcy-induced learning and memory deficits, indicating a protective effect on cognitive impairment.
Conclusions:
- Hydroxysafflor yellow A (HSYA) demonstrates significant neuroprotective properties against homocysteine (Hcy)-induced Alzheimer disease-like pathology and cognitive decline.
- HSYA may serve as a promising therapeutic candidate for managing Hcy-related neurological deficits and Alzheimer disease.
Related Concept Videos
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Role of Neurotransmitters in Memory
Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is critical for...
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is critical for...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...